Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors.

Nieto C, Centa A, Rodríguez-Rodríguez JA, Pandiella A, Martín Del Valle EM

DOI: 10.3390/nano9070948
Published: 2019 Jun 29
Container: Nanomaterials (Basel, Switzerland)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/nano9070948,
  title = {Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors.},
  author = {Nieto C and Centa A and Rodríguez-Rodríguez JA and Pandiella A and Martín Del Valle EM},
  year = {2019},
  journal = {Nanomaterials (Basel, Switzerland)},
  doi = {10.3390/nano9070948},
  url = {https://doi.org/10.3390/nano9070948}
}

RIS

TY  - JOUR
TI  - Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors.
AU  - Nieto C
AU  - Centa A
AU  - Rodríguez-Rodríguez JA
AU  - Pandiella A
AU  - Martín Del Valle EM
PY  - 2019
JO  - Nanomaterials (Basel, Switzerland)
DO  - 10.3390/nano9070948
UR  - https://doi.org/10.3390/nano9070948
ER  -

APA

C, N., A, C., JA, R., A, P., & EM, M. D. V. (2019). Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors.. Nanomaterials (Basel, Switzerland). https://doi.org/10.3390/nano9070948

Source records

pubmed · retrieved 2026-09-26T08:42:36.194Z